Durable Anti-SARS-CoV-2 Antibody Response after mRNA-1273 Booster in Peritoneal Dialysis Patients during the Omicron Wave
Abstract
:1. Introduction
2. Patients and Methods
2.1. Study Population
2.2. Peritoneal Dialysis Modalities
2.3. Serological Assessment
2.4. Statistical Analysis
3. Results
3.1. Anti-SARS-CoV-2 RBD Antibodies Declined within Six Months after the Third Dose of mRNA-1273 in SARS-CoV-2 Naive Patients
3.2. Breakthrough Infections in PD Patients within Six Months after the Third Dose of mRNA-1273
3.3. Previous Antibody Levels, High GFR, and Low Davies Comorbidity Score Are Predictors of a Robust Anti-SARS-CoV-2 Antibody Response
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
References
- Hilbrands, L.B.; Duivenvoorden, R.; Vart, P.; Franssen, C.F.M.; Hemmelder, M.H.; Jager, K.J.; Kieneker, L.M.; Noordzij, M.; Pena, M.J.; Vries, H.; et al. COVID-19-related mortality in kidney transplant and dialysis patients: Results of the ERACODA collaboration. Nephrol. Dial. Transplant. 2020, 35, 1973–1983. [Google Scholar] [CrossRef] [PubMed]
- Mahalingasivam, V.; Su, G.; Iwagami, M.; Davids, M.R.; Wetmore, J.B.; Nitsch, D. COVID-19 and kidney disease: Insights from epidemiology to inform clinical practice. Nat. Rev. Nephrol. 2022, 18, 485–498. [Google Scholar] [CrossRef] [PubMed]
- Babel, N.; Hugo, C.; Westhoff, T.H. Vaccination in patients with kidney failure: Lessons from COVID-19. Nat. Rev. Nephrol. 2022, 18, 708–723. [Google Scholar] [CrossRef] [PubMed]
- Ma, B.M.; Yap, D.Y.H.; Yip, T.P.S.; Hung, I.F.N.; Tang, S.C.W.; Chan, T.M. Vaccination in patients with chronic kidney disease-Review of current recommendations and recent advances. Nephrology 2021, 26, 5–11. [Google Scholar] [CrossRef]
- Eiselt, J.; Kielberger, L.; Rajdl, D.; Racek, J.; Pazdiora, P.; Malanova, L. Previous Vaccination and Age are More Important Predictors of Immune Response to Influenza Vaccine than Inflammation and Iron Status in Dialysis Patients. Kidney Blood Press. Res. 2016, 41, 139–147. [Google Scholar] [CrossRef]
- Mahmoodi, M.; Aghamohammadi, A.; Rezaei, N.; Lessan-Pezeshki, M.; Pourmand, G.; Mohagheghi, M.A.; Abdollahzade, S.; Mousavi-Jarrahi, A. Antibody response to pneumococcal capsular polysaccharide vaccination in patients with chronic kidney disease. Eur. Cytokine Netw. 2009, 20, 69–74. [Google Scholar] [CrossRef] [Green Version]
- Ikizler, T.A.; Coates, P.T.; Rovin, B.H.; Ronco, P. Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. Kidney Int. 2021, 99, 1275–1279. [Google Scholar] [CrossRef]
- Ashby, D.R.; Caplin, B.; Corbett, R.W.; Asgari, E.; Kumar, N.; Sarnowski, A.; Hull, R.; Makanjuola, D.; Cole, N.; Chen, J.; et al. Outcome and effect of vaccination in SARS-CoV-2 Omicron infection in hemodialysis patients: A cohort study. Nephrol. Dial. Transplant. 2022, 37, 1944–1950. [Google Scholar] [CrossRef]
- Moore, L.R.; Al-Jaddou, N.; Wodeyar, H.; Sharma, A.; Schulz, M.; Rao, A.; Abraham, K. SARS-CoV-2 in dialysis patients and the impact of vaccination. BMC Nephrol. 2022, 23, 317. [Google Scholar] [CrossRef]
- Sibbel, S.; McKeon, K.; Luo, J.; Wendt, K.; Walker, A.G.; Kelley, T.; Lazar, R.; Zywno, M.L.; Connaire, J.J.; Tentori, F.; et al. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis. J. Am. Soc. Nephrol. 2022, 33, 49–57. [Google Scholar] [CrossRef]
- Torres, R.; Toro, L.; Sanhueza, M.E.; Lorca, E.; Ortiz, M.; Pefaur, J.; Clavero, R.; Machuca, E.; Gonzalez, F.; Herrera, P.; et al. Clinical Efficacy of SARS-CoV-2 Vaccination in Hemodialysis Patients. Kidney Int. Rep. 2022, 7, 2176–2185. [Google Scholar] [CrossRef]
- Agur, T.; Zingerman, B.; Ben-Dor, N.; Alkeesh, W.; Steinmetz, T.; Rachamimov, R.; Korzets, A.; Rozen-Zvi, B.; Herman-Edelstein, M. Humoral Response to the Third Dose of BNT162b2 COVID-19 Vaccine among Hemodialysis Patients. Nephron 2022, 147, 185–192. [Google Scholar] [CrossRef]
- Attias, P.; Azzaoui, I.; El Karoui, K.; de La Selle, A.; Sokal, A.; Chappert, P.; Grimbert, P.; Fernandez, I.; Bouvier, M.; Samson, C.; et al. Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2-Recovered Dialysis Patients. Clin. J. Am. Soc. Nephrol. 2022, 17, 1008–1016. [Google Scholar] [CrossRef]
- Bensouna, I.; Caudwell, V.; Kubab, S.; Acquaviva, S.; Pardon, A.; Vittoz, N.; Bozman, D.F.; Hanafi, L.; Faucon, A.L.; Housset, P. SARS-CoV-2 Antibody Response after a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis. Am. J. Kidney Dis. 2022, 79, 185–192.e181. [Google Scholar] [CrossRef]
- Berar-Yanay, N.; Freiman, S.; Shapira, M.; Saffoury, A.; Elemy, A.; Hamze, M.; Elhaj, M.; Zaher, M.; Matanis, L.; Armaly, Z.A. Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-CoV-2 BNT162b2 mRNA Vaccine in Dialysis Patients. J. Clin. Med. 2021, 11, 64. [Google Scholar] [CrossRef]
- Davidovic, T.; Schimpf, J.; Abbassi-Nik, A.; Stockinger, R.; Sprenger-Mahr, H.; Lhotta, K.; Zitt, E. Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: Time for a boost. Kidney Int. 2021, 100, 1334–1335. [Google Scholar] [CrossRef]
- Einbinder, Y.; Perl, J.; Nacasch, N.; Bnaya, A.; Shavit, L.; Erez, D.; Shashar, M.; Halperin, T.; Grupper, A.; Benchetrit, S.; et al. Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients. Am. J. Nephrol. 2022, 53, 586–590. [Google Scholar] [CrossRef]
- Garcia, P.; Han, J.; Montez-Rath, M.E.; Sun, S.; Shang, T.; Parsonnet, J.; Chertow, G.M.; Anand, S.; Schiller, B.; Abra, G. SARS-CoV-2 Booster Vaccine Response among Patients Receiving Dialysis. Clin. J. Am. Soc. Nephrol. 2022, 17, 1036–1038. [Google Scholar] [CrossRef]
- Hsu, C.M.; Weiner, D.E.; Manley, H.J.; Aweh, G.N.; Ladik, V.; Frament, J.; Miskulin, D.; Argyropoulos, C.; Abreo, K.; Chin, A.; et al. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. Clin. J. Am. Soc. Nephrol. 2022, 17, 403–413. [Google Scholar] [CrossRef]
- Murt, A.; Dinc, H.O.; Altiparmak, M.R.; Yalin, S.F.; Yadigar, S.; Parmaksiz, E.; Kocazeybek, B.; Pekpak, M.; Ataman, M.R. Waning of SARS-CoV-2 Vaccine-Induced Immune Response over 6 Months in Peritoneal Dialysis Patients and the Role of a Booster Dose in Maintaining Seropositivity. Nephron 2022, 146, 559–563. [Google Scholar] [CrossRef]
- Broseta, J.J.; Rodriguez-Espinosa, D.; Cuadrado, E.; Rodriguez, N.; Bedini, J.L.; Maduell, F. Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients. Vaccines 2022, 10, 522. [Google Scholar] [CrossRef] [PubMed]
- Beilhack, G.; Monteforte, R.; Frommlet, F.; Reindl-Schwaighofer, R.; Strassl, R.; Vychytil, A. Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering after Six Months Adequate? Front. Med. 2022, 9, 905798. [Google Scholar] [CrossRef] [PubMed]
- Biedunkiewicz, B.; Tylicki, L.; Slizien, W.; Lichodziejewska-Niemierko, M.; Dabrowska, M.; Kubanek, A.; Rodak, S.; Polewska, K.; Tylicki, P.; Renke, M.; et al. Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose. Vaccines 2022, 10, 433. [Google Scholar] [CrossRef] [PubMed]
- Housset, P.; Kubab, S.; Pardon, A.; Vittoz, N.; Bozman, D.F.; Hanafi, L.; Caudwell, V.; Faucon, A.L. Waning but persistent humoral response 6 months after the third dose of the mRNA BNT162b2 vaccine in hemodialysis and peritoneal dialysis patients. J. Nephrol. 2022, 35, 783–785. [Google Scholar] [CrossRef]
- Quiroga, B.; Soler, M.J.; Ortiz, A.; Gansevoort, R.T.; Leyva, A.; Rojas, J.; de Sequera, P.; Network, S.C. Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis. Vaccines 2022, 10, 1738. [Google Scholar] [CrossRef]
- Manley, H.J.; Li, N.C.; Aweh, G.N.; Hsu, C.M.; Weiner, D.E.; Miskulin, D.; Harford, A.M.; Johnson, D.; Lacson, E., Jr. SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis. Am. J. Kidney Dis. 2022, 81, 406–415. [Google Scholar] [CrossRef]
- Montez-Rath, M.E.; Garcia, P.; Han, J.; Cadden, L.; Hunsader, P.; Morgan, C.; Kerschmann, R.; Beyer, P.; Dittrich, M.; Block, G.A.; et al. SARS-CoV-2 Infection during the Omicron Surge among Patients Receiving Dialysis: The Role of Circulating Receptor-Binding Domain Antibodies and Vaccine Doses. J. Am. Soc. Nephrol. 2022, 33, 1832–1839. [Google Scholar] [CrossRef]
- Beilhack, G.; Monteforte, R.; Frommlet, F.; Gaggl, M.; Strassl, R.; Vychytil, A. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients—The Vienna Cohort. Front. Immunol. 2021, 12, 780594. [Google Scholar] [CrossRef]
- Chen, C.H.; Perl, J.; Teitelbaum, I. Prescribing high-quality peritoneal dialysis: The role of preserving residual kidney function. Perit. Dial. Int. 2020, 40, 274–281. [Google Scholar] [CrossRef] [Green Version]
- Davies, S.J.; Phillips, L.; Naish, P.F.; Russell, G.I. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol. Dial. Transplant. 2002, 17, 1085–1092. [Google Scholar] [CrossRef] [Green Version]
- Bates, D.; Mächler, M.; Bolker, B.; Walker, S. Fitting Linear Mixed-Effects Models Using lme4. J. Stat. Softw. 2015, 67, 1–48. [Google Scholar] [CrossRef]
- Kuznetsova, A.; Brockhoff, P.B.; Christensen, R.H.B. lmerTest Package: Tests in Linear Mixed Effects Models. J. Stat. Softw. 2017, 82, 1–26. [Google Scholar] [CrossRef] [Green Version]
- Quiroga, B.; Soler, M.J.; Ortiz, A.; Jarava Mantecon, C.J.; Gomes Perez, V.O.; Bordils, A.; Lacueva, J.; Marin Franco, A.J.; Delgado Conde, P.; Munoz Ramos, P.; et al. Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: A prespecified analysis of the SENCOVAC study. Nephrol. Dial. Transplant. 2022, 38, 969–981. [Google Scholar] [CrossRef]
- Wand, O.; Nacasch, N.; Fadeela, A.; Shashar, M.; Grupper, A.; Benchetrit, S.; Erez, D.; Shitrit, P.; Cohen-Hagai, K. Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients. J. Nephrol. 2022, 35, 1479–1487. [Google Scholar] [CrossRef]
- El Haggan, W.; Berdin, B.; El Salhy, M. Antibody titers against SARS-CoV-2 spike protein 6 months after a third BNT162b2 vaccine in chronic hemodialysis patients. Clin. Kidney J. 2022, 15, 1202–1203. [Google Scholar] [CrossRef]
- Tanriover, C.; Ucku, D.; Basile, C.; Tuttle, K.R.; Kanbay, M. On the importance of the interplay of residual renal function with clinical outcomes in end-stage kidney disease. J. Nephrol. 2022, 35, 2191–2204. [Google Scholar] [CrossRef]
- Kato, S.; Chmielewski, M.; Honda, H.; Pecoits-Filho, R.; Matsuo, S.; Yuzawa, Y.; Tranaeus, A.; Stenvinkel, P.; Lindholm, B. Aspects of immune dysfunction in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 2008, 3, 1526–1533. [Google Scholar] [CrossRef] [Green Version]
- Rozen-Zvi, B.; Yahav, D.; Agur, T.; Zingerman, B.; Ben-Zvi, H.; Atamna, A.; Tau, N.; Mashraki, T.; Nesher, E.; Rahamimov, R. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: A prospective cohort study. Clin. Microbiol. Infect. 2021, 27, 1173.e1–1173.e4. [Google Scholar] [CrossRef]
- Kanai, D.; Wakui, H.; Haze, T.; Azushima, K.; Kinguchi, S.; Kanaoka, T.; Toya, Y.; Hirawa, N.; Kato, H.; Uneda, K.; et al. Improved Immune Response to the Third COVID-19 mRNA Vaccine Dose in Hemodialysis Patients. Kidney Int. Rep. 2022, 7, 2718–2721. [Google Scholar] [CrossRef]
- Rincon-Arevalo, H.; Choi, M.; Stefanski, A.L.; Halleck, F.; Weber, U.; Szelinski, F.; Jahrsdorfer, B.; Schrezenmeier, H.; Ludwig, C.; Sattler, A.; et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci. Immunol. 2021, 6, eabj1031. [Google Scholar] [CrossRef]
- Zitt, E.; Hafner-Giessauf, H.; Wimmer, B.; Herr, A.; Horn, S.; Friedl, C.; Sprenger-Mahr, H.; Kramar, R.; Rosenkranz, A.R.; Lhotta, K. Response to active hepatitis B vaccination and mortality in incident dialysis patients. Vaccine 2017, 35, 814–820. [Google Scholar] [CrossRef] [PubMed]
- Dekervel, M.; Henry, N.; Torreggiani, M.; Pouteau, L.M.; Imiela, J.P.; Mellaza, C.; Garnier, A.S.; Dujardin, A.; Asfar, M.; Ducancelle, A.; et al. Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis. Clin. Kidney J. 2021, 14, 2349–2355. [Google Scholar] [CrossRef] [PubMed]
- Tillmann, F.P.; Figiel, L.; Ricken, J.; Still, H.; Korte, C.; Plassmann, G.; von Landenberg, P. Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study. J. Clin. Med. 2021, 10, 5113. [Google Scholar] [CrossRef] [PubMed]
- Panizo, N.; Albert, E.; Gimenez-Civera, E.; Puchades, M.J.; D’Marco, L.; Gandia-Salmeron, L.; Gimenez, E.; Torre, I.; Sancho, A.; Gavela, E.; et al. Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within 3 months after COVID-19 full vaccination. Clin. Kidney J. 2022, 15, 1562–1573. [Google Scholar] [CrossRef] [PubMed]
- Piotrowska, M.; Zielinski, M.; Tylicki, L.; Biedunkiewicz, B.; Kubanek, A.; Slizien, Z.; Polewska, K.; Tylicki, P.; Muchlado, M.; Sakowska, J.; et al. Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated with Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized with BNT162b2 Pfizer-BioNTech SARS-CoV-2 Vaccine. Front. Immunol. 2022, 13, 832924. [Google Scholar] [CrossRef]
- Earle, K.A.; Ambrosino, D.M.; Fiore-Gartland, A.; Goldblatt, D.; Gilbert, P.B.; Siber, G.R.; Dull, P.; Plotkin, S.A. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021, 39, 4423–4428. [Google Scholar] [CrossRef]
- Fu, J.; Shen, X.; Anderson, M.; Stec, M.; Petratos, T.; Cloherty, G.; Montefiori, D.C.; Landay, A.; Moy, J.N. Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naive and Convalescent BNT162b2 Recipients. Vaccines 2022, 10, 1904. [Google Scholar] [CrossRef]
- Feng, S.; Phillips, D.J.; White, T.; Sayal, H.; Aley, P.K.; Bibi, S.; Dold, C.; Fuskova, M.; Gilbert, S.C.; Hirsch, I.; et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 2021, 27, 2032–2040. [Google Scholar] [CrossRef]
- Goldblatt, D.; Alter, G.; Crotty, S.; Plotkin, S.A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 2022, 310, 6–26. [Google Scholar] [CrossRef]
- Khoury, D.S.; Cromer, D.; Reynaldi, A.; Schlub, T.E.; Wheatley, A.K.; Juno, J.A.; Subbarao, K.; Kent, S.J.; Triccas, J.A.; Davenport, M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021, 27, 1205–1211. [Google Scholar] [CrossRef]
Patient Demographics | Total (n = 27) |
---|---|
Age (years, mean, range) | 54.9 (33–76) |
Men (%) | 17 (63) |
Davies Comorbidity Score (%) | |
0 | 11 (41) |
1 | 9 (33) |
2 | 5 (19) |
3 | 2 (7) |
4 | 0 |
5 | 0 |
Dialysis vintage, months median (IQR) | 21.5 (13.4–38.7) |
Weekly total (renal + peritoneal) Kt/V median (IQR) | 1.94 (1.76–2.10) |
GFR (mL/min) median (IQR) | 1.86 (0.65–4.67) |
Laboratory (mean ± SD) | |
Hemoglobin (g/dL) | 10.4 ± 1.3 |
Leukocytes (G/L) | 7.66 ± 2.19 |
Thrombocytes (G/L) | 230 ± 76.5 |
Albumin (g/L) | 36.3 ± 4.37 |
Sodium (mmol/L) | 135 ± 3.65 |
Potassium (mmol/L) | 4.28 ± 0.51 |
Calcium (mmol/L) | 2.24 ± 0.21 |
Phosphate (mmol/L) | 1.93 ± 0.44 |
Bicarbonate (mmol/L) | 26.6 ± 2.76 |
C-reactive protein (mg/dL) | 0.78 ± 1.02 |
Medication n, (%) | |
Immunosuppressive therapy | 5 (18.5) |
RAAS-inhibitor medication | 14 (51.8) |
Vitamin D medication | 18 (66.7) |
Antibody Titer (BAU/mL) | |||
---|---|---|---|
Total Population (n = 27) | SARS-CoV-2 Naive Patients (n = 19) | SARS-CoV-2 Infected Patients (n = 8) * | |
6 months after 2nd dose | 185 (88–757) | 212 (99–783) | 156 (83–542) |
1 month after 3rd dose | 19,405 (8884–40,650) | 21,424 (11,402–43,650) | 9927 (8222–22,586) |
6 months after 3rd dose | 6832 (1839–27,690) | 5120 (768–7159) | 73,500 (23,815–111,825) |
Age (Years) | Sex | Days between 3rd Dose and Infection | Clinical Symptoms | Outcome | Antibody Titer (Median, BAU/mL) | |
---|---|---|---|---|---|---|
1 Month after 3rd Dose | 6 Months after 3rd Dose | |||||
54 | M | 69 | Mild | Favorable | 9927 | 109,800 |
33 | F | 82 | Mild | Favorable | 51,900 | 124,200 |
59 | M | 86 | Mild | Favorable | 9620 | 116,100 |
43 | M | 92 | Mild | Favorable | 16,214 | 110,400 |
35 | F | 109 | Mild | Favorable | 41,700 | 27,690 |
38 | F | 125 | None | Favorable | 1820 | 37,200 |
56 | M | 130 | None | Favorable | 9927 | 12,190 |
55 | M | 156 | None | Favorable | 4029 | 6832 |
Coefficient | F Value | p-Value | |
---|---|---|---|
Anti-SARS-CoV-2 RBD levels after 1st dose | 1.67 | 87.20 | 1.95 × 10−11 |
Davies Comorbidity Score | −0.48 | 4.87 | 0.034 |
GFR | 0.13 | 4.25 | 0.047 |
Age | −0.03 | 2.47 | 0.12 |
Gender (male) | −0.61 | 1.28 | 0.27 |
Ferritin | 0.0005 | 0.61 | 0.44 |
Albumin | 0.107 | 2.12 | 0.15 |
Vitamin D | −0.02 | 3.91 | 0.055 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Beilhack, G.; Monteforte, R.; Frommlet, F.; Reindl-Schwaighofer, R.; Strassl, R.; Vychytil, A. Durable Anti-SARS-CoV-2 Antibody Response after mRNA-1273 Booster in Peritoneal Dialysis Patients during the Omicron Wave. Vaccines 2023, 11, 1121. https://doi.org/10.3390/vaccines11061121
Beilhack G, Monteforte R, Frommlet F, Reindl-Schwaighofer R, Strassl R, Vychytil A. Durable Anti-SARS-CoV-2 Antibody Response after mRNA-1273 Booster in Peritoneal Dialysis Patients during the Omicron Wave. Vaccines. 2023; 11(6):1121. https://doi.org/10.3390/vaccines11061121
Chicago/Turabian StyleBeilhack, Georg, Rossella Monteforte, Florian Frommlet, Roman Reindl-Schwaighofer, Robert Strassl, and Andreas Vychytil. 2023. "Durable Anti-SARS-CoV-2 Antibody Response after mRNA-1273 Booster in Peritoneal Dialysis Patients during the Omicron Wave" Vaccines 11, no. 6: 1121. https://doi.org/10.3390/vaccines11061121
APA StyleBeilhack, G., Monteforte, R., Frommlet, F., Reindl-Schwaighofer, R., Strassl, R., & Vychytil, A. (2023). Durable Anti-SARS-CoV-2 Antibody Response after mRNA-1273 Booster in Peritoneal Dialysis Patients during the Omicron Wave. Vaccines, 11(6), 1121. https://doi.org/10.3390/vaccines11061121